Migraine
Conditions
Interventions
Migraine Group (Case Group):None
Control Group (Non-Migraine Group):None
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Case Group (Migraine Group): (1) Meets the diagnostic criteria for migraine (it is recommended to follow ICHD-3, assessed and recorded by a neurology or neurosurgery team); (2) Undergoes peripheral nerve transection/related surgical procedures due to clinical treatment needs, and peripheral nerve tissue can be obtained during surgery; (3) This study intends to apply for a waiver of informed consent (retrospective, minimal risk, using leftover tissue and de-identified data); if the ethics committee requires supplementary consent for some cases, it will be carried out according to their recommendations. 2. Control Group (Non-Migraine Group): (1) Undergoes removal of peripheral nerve tissue due to other surgical indications, and the excised tissue can be obtained during surgery; (2) Has no history of migraine diagnosis or recurrent headache (based on medical records and preoperative evaluation); (3) This study intends to apply for a waiver of informed consent (retrospective, minimal risk, using leftover tissue and de-identified data); if the ethics committee requires supplementary consent for some cases, it will be carried out according to their recommendations.
Exclusion criteria
Exclusion criteria: 1.Participants with comorbid conditions that may significantly affect the peripheral nerve microenvironment will be excluded, including peripheral neuritis or neuropathies (such as diabetic peripheral neuropathy and hereditary neuropathies), as well as active systemic autoimmune diseases (e.g., systemic lupus erythematosus and vasculitis). 2.Control participants will be excluded if the harvested peripheral nerve shows evidence of tumor involvement, significant inflammation or infection, severe traumatic changes, or pathological findings suggestive of neuritis or extensive degeneration, as determined by intraoperative findings, pathological reports, or imaging records. 3.Participants who have received systemic immunomodulatory therapy within the past 3 months (including long-term corticosteroids, immunosuppressive agents, or biologic therapies), or who have active infections will be excluded. Eligibility will be verified based on the institutional electronic medical records, prescription/medication lists, and hospitalization records. Cases with unverifiable information will be recorded as missing data and handled in sensitivity analyses. 4.Samples will be excluded if they fail to meet quality criteria, including tissue necrosis or severe mechanical damage, insufficient cell viability, significant RNA degradation, or failure to pass sequencing quality control metrics. 5.Participants will be excluded if critical clinical data are substantially missing, such that key confounding variables (e.g., sampling site or nerve type) cannot be reliably documented.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Single-nucleus RNA sequencing (snRNA-seq); | — |
Countries
China
Contacts
Public ContactChongjie Cheng
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed